Joe Jimenez, CEO of Novartis, discusses the $5 billion share buyback program. He also says the Novartis pipeline is very strong, with many upcoming blockbuster drugs.
Carl Berg, billionaire venture capitalist and co-founder, Berg and Berg, sees huge opportunities in life sciences. Berg Pharma has the opportunity to revolutionize health care by using biology to determine differences between a healthy and unhealthy person.
Stefan Dobocky, board member at DSM, says that by merging its pharma division with drug maker Patheon, a "global leader" will be created, and explains that the new entity will be run as a separate company.
Focused on high-risk heart attack and stroke patients, the new recommendation are for aggressive drug therapy to lower cholesterol.
Amazon.com is clashing with Johnson & Johnson amid complaints the online retailer hasn't stopped sales of damaged or expired products.
Johnson & Johnson and its subsidiaries were accused of promoting powerful psychiatric drugs for unapproved uses in children, seniors and disabled patients.
Pfizer reported quarterly earnings that beat analysts' expectations on Tuesday, but it lowered its guidance for its full-year guidance.
Barbara Ryan, FTI Consulting managing director, breaks down the pharmaceutical company's earnings and weighs in on two promising drugs in the pipeline, as the company ramps up research and development.
Merck reported better-than-expected earnings, but sales of its Januvia diabetes treatment fell, raising more concerns about the company's growth prospects.
Consumer goods group Reckitt Benckiser is reviewing options for its pharmaceuticals unit.
Andrew Weiss, head of pharma and biotech research at Vontobel, says most products in Novartis' pipeline will face tough competition and incur large marketing costs.
Concerns that flu could mean an increase in staff sick days has prompted some companies to arrange flu jabs for their employees – boosting sales for some drugs companies.
Johnson & Johnson reported better than expected quarterly results on strong growth for its prescription drugs.
Andrew Weiss, head of pharma and biotech research at Vontobel, says Roche's plan reflects the Swiss pharmaceutical giant's strong pipeline.
GlaxoSmithKline has confirmed plans to seek regulatory approval for a malaria vaccine in 2014, boosting hopes that the drug could be widely available within a couple of years.
Merck announced plans to slash an additional 8,500 jobs, and said it aims to cut expenses by $2.5 billion by 2015.
Research shows long-term use of opioids is often ineffective in treating chronic pain, says Barry Meier, New York Times reporter.
There are a handful of stocks out there that the market loves and should take even higher by the end of the year, CNBC's Jim Cramer said Thursday.
Stanley Crooke, Isis Pharmaceuticals chairman & CEO, discusses his company's strategic new partnership in the treatment of neurological disorders using antisense therapy.
After two decades of research, a treatment that slows or reverses the progression of Alzheimer's has proved elusive. The aging of the global population makes the need more urgent.